Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn

• https://twitter.com/synovialjoints/status/1801875376911638774/photo/1

NEW biomarkers in #MAS 1️⃣ IL-18 (available at some 🏥)⭐️ 2️⃣ S100A12 3️⃣ CXCL9/10 🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder! 🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷 #macrophage #EULAR2024 #genetics #rheumx https://t.co/Uot3JjrWs8

• https://twitter.com/AMinalyan/status/1801623040796545505/photo/1
• https://twitter.com/AMinalyan/status/1801623040796545505/photo/1

Potential efficacy of JAK inhibitors in VEXAS syndrome #EULAR2024 NZ https://t.co/HziLUgo1gA

• https://twitter.com/ARD_BMJ/status/1801537612353560628/photo/1

#Behcet’s #syndrome is increasing in the UK ? ⬆️ Detection ? Changing population demographics ? Other reasons Poster discussion POS0258 #EULAR2024 @RheumNow @eular_org @Pr1yankaC https://t.co/SEzmJnFMhM

• https://twitter.com/Janetbirdope/status/1801530101282070779/photo/1
• https://twitter.com/Janetbirdope/status/1801530101282070779/photo/1

Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 ! Amazing pictures to explain cellular level pathophysiology! Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE

• https://twitter.com/bella_mehta/status/1801356814581223729/photo/1

STAR responder may be the way to go! Less placebo effect than CREST. Better in patients with low systemic activity. https://t.co/mMYOKfG2gS

• https://twitter.com/bella_mehta/status/1801260166358110234/photo/1
• https://twitter.com/bella_mehta/status/1801260166358110234/photo/1
• https://twitter.com/bella_mehta/status/1801260166358110234/photo/1
• https://twitter.com/bella_mehta/status/1801260166358110234/photo/1

FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/dZ21V2cKwR https://t.co/QADVP2w3Tz

• RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older…